BMY stock: buy or sell?

BMY stock price: $50.57 1.00% At close on September 20th, 2019

Updated on:
September 20th, 2019


Bristol-Myers Squibb shares stepped up 1.00% to $50.57 today. Friday was the 5th green day in a row, gaining 2.30%.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide.

Should I buy BMY stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Bristol-Myers Squibb stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Bristol-Myers Squibb stock a buy?

Banks and financial institutions publish stock ratings everyday. At, we collected 15 ratings published for BMY stock in the last 30 days.

The general sentiment of these ratings is bullish for BMY stock, with 9 positive ratings.
Is BMY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-9-4Peel Huntn/aBuy
2019-9-3Bank of American/aNeutral
2019-8-14Atlantic SecuritiesNeutralOverweight
2019-6-13UBS Groupn/aNeutral
2019-5-3JPMorgan Chase & Co.OverweightOverweight
2019-5-3JPMorgan Chase & Co.n/aOverweight
2019-5-3BarclaysEqual WeightOverweight
2019-5-28Goldman Sachs Groupn/aBuy
2019-3-20BMO Capital Marketsn/aOutperform
2019-2-4Credit Suisse Groupn/aHold
2019-2-19BMO Capital Marketsn/aBuy
2019-2-19Bank of AmericaNeutralHold
2019-2-15Credit Suisse Groupn/aHold
2019-1-4Edward JonesBuyHold
2019-1-3BMO Capital Marketsn/aBuy

BMY stock analysis

Daily outlook

Shares of Bristol-Myers Squibb closed today at $50.57 and stepped up a tiny 1.00%.

Bristol-Myers Squibb shares stepped up 1.00% to $50.57 today. In the last 25 days when BMY stock price broke up the SMA200d line, it gained $3.99 (8.57%). For the last 8 days when SMA50d and SMA100d crossed up, BMY price gained $1.33 per share (2.70%).

BMY stock chart (daily)

Weekly outlook

Bristol-Myers Squibb stepped up a fine 2.31% this week. Counting this, it's been 4 green weeks in a row, gaining $3.99 or 8.49%.

Since late August when BMY stock price broke up the SMA40w line, it gained $3.99 (8.57%).

BMY stock chart (weekly)

BMY stock price history

BMY stock historical price chart

BMY stock reached 52-week highs on October at $62.09, and all-time highs 2016-07-15 with a price of 70.79.

BMY stock price target is $56.50

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' BMY stock price predictions in the hope that they will be met as they may be wrong and not met. We found 11 price predictions for Bristol-Myers Squibb stock published in the last 30 days:
BMY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-9-3Bank of AmericaRaises Target$46.00$49.006.5%
2019-6-13UBS GroupLowers Target$55.00$51.00-7.3%
2019-5-3JPMorgan Chase & Co.Reiteratesn/a$62.00-
2019-5-28Goldman Sachs GroupInitiatesn/a$54.00-
2019-3-20BMO Capital MarketsRaises Targetn/a$62.00-
2019-2-4Credit Suisse GroupSet Price Targetn/a$59.00-
2019-2-19BMO Capital MarketsReiteratesn/a$59.00-
2019-2-19Bank of AmericaReiterates$53.00$51.00-3.8%
2019-2-15Credit Suisse GroupReiteratesn/a$59.00-
2019-1-3BMO Capital MarketsReiteratesn/a$60.00-
(in average)$51.80$56.509.0%
The price forecast for Bristol-Myers Squibb stock is $56.50, moving in a range between $62.00 and $49.00. In average, analysts' outlook on BMY price target is positive, improving the target by a 9.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since last April, when Bristol-Myers Squibb published its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will extend this review.
BMY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a pretty good increase of 8.59% to $22,561.00 M dollars. Aligned with this, its income margin (compared to sales) boosted to 21.81%, that is $4,920.00 million.

Bristol-Myers Squibb fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Bristol-Myers Squibb TTM sales up to March 2019 were $23,288.00 and income $5,144.00 million dollars. When comparing this TTM figures with the last reported annuality, we can esteem Bristol-Myers Squibb business evolution since December 2018: Annual revenues up to March, compared to lastest yearly report, appreciated a beatiful 3.22%. Nonetheless, profit margin (net income/revenues) stayed steady at 21.81%.

BMY annual Sales and Income evolution
2013$16,390 M-$2,560 M15.6%-
2014$15,879 M-3.12%$2,004 M12.6%-21.72%
2015$16,560 M4.29%$1,565 M9.5%-21.91%
2016$19,427 M17.31%$4,457 M22.9%184.79%
2017$20,776 M6.94%$1,007 M4.8%-77.41%
2018$22,561 M8.59%$4,920 M21.8%388.58%
TTM $23,288 M3.22%$5,144 M22.1%4.55%

Quarterly financial results

Bristol-Myers Squibb reported $5,920.00 million in revenues for 2019-Q1, a -0.89% less compared to previous quarter. Reported quarter earnings marked $1,710.00 million with a profit margin of 28.89%. Profit margin rose a 9.46% compared to previous quarter when profit margin was 19.42%. When comparing sales to same quarter last year, Bristol-Myers Squibb sales marked an outstanding growth and climbed a 14.00%.
BMY quarterly Sales and Income evolution
2017-Q2$5,140 M-$916 M17.8%-
2017-Q3$5,250 M2.14%$845 M16.1%-7.75%
2017-Q4$5,449 M3.79%$-2,328 M-42.7%-375.50%
2018-Q1$5,193 M-4.70%$1,486 M28.6%-163.83%
2018-Q2$5,704 M9.84%$373 M6.5%-74.90%
2018-Q3$5,691 M-0.23%$1,901 M33.4%409.65%
2018-Q4$5,973 M4.96%$1,160 M19.4%-38.98%
2019-Q1$5,920 M-0.89%$1,710 M28.9%47.41%

Bristol-Myers Squibb ownership

When you are planning to buy shares of a company, it's always worth to have a look its ownership structure.

Bristol-Myers Squibb shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.11% of all shares.

In case of Bristol-Myers Squibb stock, 75.05% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for BMY stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

Market cap$82.9 B
Total shares1,640.0 M
Float shares1,630.0 M
  - Institutional holdings (%)75.0%
  - Insider holdings (%)0.1%
Shares in short selling0.0%

BMY summary

Friday, September 20th, 2019
Day range$49.99 - $50.86
Previous close$50.07
Session gain1.00%
Average true range$0.84
50d mov avg$46.78
100d mov avg$46.55
200d mov avg$47.51
Daily pattern
Weekly pattern

Bristol-Myers Squibb performance

To better understand Bristol-Myers Squibb performance you must compare its gains with other related stocks in same sector or industry. We selected as the bechmarking frame for Bristol-Myers Squibb stock.
BMYBristol-Myers Squ...3.39%6.87%-16.14%

Bristol-Myers Squibb competitors

Unfortunately, we could not find any public company that could be defined as Bristol-Myers Squibb competitor. This doesn't mean Bristol-Myers Squibb does not have any competitor in the market, it's just we could not detected it.

    Latest BMY stock news